Biogen’s initial launch price of $56,000 a year for Aduhelm led to an increase of nearly $22 in Medicare’s monthly “Part B” premium for outpatient care, the largest ever in dollar terms but not percentage-wise.
Medicare attributed about half of this year’s increase to contingency planning for Aduhelm. Faced with skepticism over its medication, Biogen recently slashed the price to $28,200, but Medicare enrollees were already on the hook for the $170.10 premium. Health and Human Services Secretary Xavier Becerra has directed Medicare to reassess the premium increase.
Nonetheless, the high price of Aduhelm and the fact that most of the 6 million Americans with Alzheimer’s are old enough to be covered by Medicare stretched the limits. The medicine, administered by IV in a doctor’s office, hasn’t been shown to reverse or significantly slow Alzheimer’s. But the FDA said that its ability to reduce clumps of plaque in the brain is likely to slow dementia.
“Too many patients are not being offered the choice of Aduhelm due to financial considerations and are thus progressing beyond the point of benefitting from the first treatment to address an underlying pathology of Alzheimer’s disease,” CEO Michel Vounatsos said at the time. “We recognize that this challenge must be addressed in a way that is perceived to be sustainable for the U.S. healthcare system.
Biogen said in June, shortly after the FDA approval, that about 900 sites in the U.S. have the equipment and expertise to immediately begin giving the drug, which requires monthly infusion.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Medicare proposes coverage limits for Alzheimer’s drug AduhelmMounting premium pressures contributed to the determination.
Les mer »
Medicare told to reassess premium hike after price slashed on Biogen Alzheimer's drugDepartment of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was part of the reason for the boost.
Les mer »
Medicare Told to Reassess Premium Hike for Alzheimer's DrugU.S. health secretary Xavier Becerra is ordering Medicare to reassess a big premium increase facing millions of seniors this year
Les mer »
U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patientsThe U.S. government Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc's Aduhelm but will require patients to be enrolled in a clinical trial, potentially limiting access.
Les mer »
Medicare is about to make its most important coverage decision in years. Here’s how people with Alzheimer’s and others might be affected.A controversial new drug is roiling the medical community and driving up Medicare premiums.
Les mer »